This Book >>

  • 385pp. Published January 2016
  • Scientific Research Publishing, Inc., USA.
  • Category: Medicine & Healthcare
  • ISBN: 978-1-61896-144-0
  • (Hardcover) USD 109.00
  • ISBN: 978-1-61896-143-3
  • (Paperback) USD 89.00
Authors/Editors Price: 40% off
Buy at:

Connect with SCIRP >>

Contact Us >>

Home > Books > Advances in HIV-1Vaccine Volume I
Advances in HIV-1Vaccine Volume I
  • Description
  • Author(s) Information
Since the human immunodeficiency virus (HIV) was identified as the causative agent of acquired immunodeficiency syndrome (AIDS), the Human Immunodeficiency Virus (HIV) represents a worldwide threat to public health and the economy. It has been estimated that 35.3 (32.2-38.8) million people were living with HIV globally at the end of 2012. HIV has two major types, HIV-1 and HIV-2, which are further divided into groups, subtypes and recombinant forms. Globally, over 90% of HIV infections belong to HIV-1 group M viruses. Despite of the successful use of highly active antiretroviral therapy, the high genetic diversity of the HIV genomehas challenged the development of drugs and vaccines. Twenty-five years of research into development of a vaccine to prevent or control HIV-1 infection doesn’t lead to available protective vaccines. The aim of this book is to provide an overview of the status of research within the HIV vaccine.
Components of the Book:
  • Chapter 1
    Therapeutic HIV Vaccines: Prior Setbacks, Current Advances, and Future Prospects
  • Chapter 2
    Development of Prophylactic Vaccines against HIV-1
  • Chapter 3
    An Integrated Map of HIVGenome-Wide Variation from a Population Perspective
  • Chapter 4
    The HIV-1 Pandemic: Does the Selective Sweep in Chimpanzees Mirror Humankind’s Future?
  • Chapter 5
    HIV-1 Vaccine Immunogen Design Strategies
  • Chapter 6
    HIV Vaccine-Induced Sero-Reactivity: A Challenge for Trial Participants, Researchers, and Physicians
  • Chapter 7
    Immune Quiescence: AModel of Protection against HIV Infection
  • Chapter 8
    Immunogenicity of a Recombinant Measles HIV-1 Subtype C Vaccine
  • Chapter 9
    The HIV Glycan Shield as a Target for Broadly Neutralizing Antibodies
  • Chapter 10
    The Role of Neutralizing Antibodies in Prevention of HIV-1 Infection: What Can We Learn from the Mother-to-Child Transmission Context?
  • Chapter 11
    Identification of Broadly Neutralizing Antibody Epitopes in the HIV-1 Envelope Glycoprotein Using Evolutionary Models
  • Chapter 12
    HIV-1 Envelope Glycoprotein Signatures that Correlate with the Development of Cross-Reactive Neutralizing Activity
Readership: Clinical practitioners and scientists in HIV vaccine and immunology; immunological researchers; medical, medicinal and immunological students and those with an interest in HIV vaccine.
comments powered by Disqus